complex is transported to the nucleus where receptor proteins. The steroid-receptor testosterone appears to depend on reduction to testosterone as reported in the literature, considerable variations of the half-life of is metabolized to various 17-keto steroids concentration will determine its half-life. and bound forms, and the free testosterone binding globulin in the plasma will determine translationally effective blood levels for full replacement liver of the first pass. Oral doses as high as Pharmacokinetics surgery, convalescence and functional uter­
inhibition of pituitary follicle stimulating hor­
production of erythropoietic stimulating factor. Androgens in fusion of the epiphyseal growth centers and maturation. Use over long periods may result about by fusion of the epiphyseal growth centers. In children, exogenous androgens termination of growth process. Androgens in fusion of the epiphyseal growth centers. In children, exogenous androgens termination of linear growth which is brought accelerates linear growth rates, but may cause centers. In children, exogenous androgens about by fusion of the epiphyseal growth 
impression of calcium. Androgens have been reported increase protein anabolism and decrease to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase protein anabolism and decrease of calcium. Androgens have been reported to increase pro
Pharmacological Action

Android® contains methyltestosterone, an anabolic steroid with mineralocorticoid-like activity. It is anabolic in nature and is used for replacement therapy in patients suffering from androgen deficiency, underactive or non-functional testes, and for maintenance treatment of androgen-dependent diseases. This medication is not intended for use as anabolic agents for athletes and is not approved for this purpose.

Indications

Android® is indicated for the treatment of androgen-deficient men. It is also used for the maintenance treatment of androgen-dependent conditions such as breast cancer, polycythemia, and prostatic carcinoma. The medication is administered orally, and the dosage is individualized based on the patient's response and tolerance. The recommended dosage is 2.5 to 15 mg daily.

Contraindications

Android® is contraindicated in patients with known hypersensitivity to methyltestosterone or any of its excipients. It is also contraindicated in patients with liver disease, severe cardiovascular disease, or those at risk for developing these conditions.

Adverse Reactions

Common side effects of Android® include fluid retention, ankle swelling, high blood pressure, bloating, edema, and muscle and joint pain. Other possible adverse reactions include gynecomastia, increased risk of myocardial infarction, and stroke. Rare side effects may include anaphylactoid reactions and low potassium levels.

Precautions

Android® is classified as a schedule III Controlled Substance under the Anabolic Steroids Act. It is available in Canada only through a prescription from a doctor. The medication should be stored at 25°C (77°F) and not exposed to direct sunlight.

Drug/Laboratory Test Interferences

Android® may interfere with the determination of certain laboratory tests, such as tests for liver function and thyroid function. Patients should inform their healthcare providers of their medication use before undergoing any laboratory tests.

Drug Interactions

Android® should not be used concurrently with other drugs that can increase blood pressure or cause fluid retention. These include antihypertensives, diuretics, and some antidepressants. Patients should consult their healthcare providers before starting any new medications while taking Android®.

Dosage and Administration

The dosage of Android® is individualized based on the patient's response and tolerance. The recommended dosage is 2.5 to 10 mg daily. The medication is administered orally, with or without food. The dosage may be increased or decreased based on the patient's response and the development of adverse effects.

Contraindications and Precautions

Android® is contraindicated in patients with liver disease, severe cardiovascular disease, or those at risk for developing these conditions. It is also contraindicated in patients with known hypersensitivity to methyltestosterone or any of its excipients. The medication should be used with caution in pregnant women and lactating mothers. It is not recommended for use by children.

Overdosage

Overdosage of Android® may result in symptoms such as fluid retention, ankle swelling, high blood pressure, bloating, and edema. In case of overdose, medical attention should be sought immediately.

Missed Doses

If a dose of Android® is missed, it should be taken as soon as possible. The next dose should be taken at the regular time. If it is almost time for the next dose, the missed dose should be skipped and the regular dose taken as usual. Do not double the dose to compensate for the missed one.
Each capsule contains 10 mg methylTESTOSTERone, USP.

Usual Dosage: See accompanying package insert.

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Manufactured for:
Valient Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA

By:
Valient Canada LP
1956 Bourdon Street
Montreal, Quebec, H4M 1V1

Made in Canada

Dispense in tight, light-resistant containers as defined in USP.
Androgens are indicated for replacement therapy in hypogonadal states and for the enhancement of athletic performance. Because of the potential risk associated with the use of androgens, patients being considered for such therapy should be thoroughly counseled regarding the nature of their disease, the purpose of androgen therapy, and the possible risks and side effects. Androgen therapy should be used cautiously in men with a history of coronary artery disease and the patient and parents should be informed of the possible risk of gynecomastia. Patients with preexisting liver dysfunction should be closely monitored during androgen therapy. Patients with prostate carcinoma should not be treated with androgens, and therapy in these women include ablation of the gonads or the administration of a Gonadotropin or luteinizing hormone-releasing hormone (LHRH) agonist.
MethylTESTOSTERone capsules USP

10 mg are red capsules imprinted “VRX 10” on both sections. They are available in bottles of 100.

9410201 Revision 04/15

Made in Canada
Montreal, Quebec, H4M 1V1

Manufactured for:

DOSAGE AND ADMINISTRATION

Replacement therapy in androgen-deficiency
conditions (See INDICATIONS AND USAGE and WARNINGS).

Doses used in delayed puberty generally
are in the lower range of that given above,
with adjustments made according to the
developmental stage of the patient.

The usual dosage in adult males who
are to receive therapy for at least six months
is 10 to 15 mg intramuscularly or subcutaneously three times per week. A dosage of 20 mg
three times per week may be necessary in
some instances. The dosage may be increased
in increments of 10 mg every six months up to
a maximum daily dose of 60 mg. Dosage is
adjusted according to the patient’s sex, and
diagnosis of the individual patient. For
adolescent males, the dosage of MethylTESTOSTERone capsules USP should be
adjusted so that the dose is proportional to
the patient’s weight (See INDICATIONS AND
USAGE and WARNINGS).

The initial dosage in adult females
who are to receive therapy for at least six months
is 1 mg/day in divided doses.
Each capsule contains 10 mg methylTESTOSTERone, USP.

Usual Dosage:
See accompanying package insert.

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Room Controlled Temperature].

Dispense in tight, light-resistant containers as defined in USP.

Manufactured for:
Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA

By:
Valeant Canada LP
1956 Bourdon Street
Montreal, Quebec, H4M 1V1

Made in Canada